Current Report Filing (8-k)
12 Août 2014 - 12:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported): August
11, 2014
CardioGenics Holdings Inc.
(Exact Name of Registrant as Specified in its
Charter)
Nevada |
|
000-28761 |
|
88-0380546 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification) |
6295 Northam Drive, Unit 8, Mississauga, Ontario,
L4V 1W8
(Address of Principal Executive Offices)(Zip
Code)
Registrant’s telephone number, including
area code: 905.673.8501
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 – Other Events
In its Current Report on Form 8-K filed
on June 13, 2014, CardioGenics Holdings Inc. (the “Company”) reported that it had entered into
subscription agreements with 13 investors (including three institutional investors) for the sale and issuance of 12,000,000
shares of its common stock (the “Private Placement Shares”) in exchange for $1,300,000, or $0.11 per
share (the “Polish Offering”).
On July 25, 2014, the Company was informed
by WDM Autoryzowny Doradca Sp. Z o.o., which was providing advisory services to the Company in connection with the listing of the
Private Placement Shares on the NewConnect Market of the Warsaw Stock Exchange (the “Advisor”) and WDM Dom Maklerski
S.A., which was acting as the offering agent for the Polish Offering (the “Offering Agent”), that efforts to
list the Private Placement Shares on the NewConnect Market were being terminated due to the Company not currently meeting the shareholder
equity requirements of the Warsaw Stock Exchange and the unlikelihood that it will be able to do so in the near term. The Advisor
also cited the approximate 50% decrease in the Company’s stock price from June 1, 2014 to July 1, 2014 as a significant concern.
The Advisor and the Offering Agent also informed
the Company that their respective agreements with the Company have been terminated and the proceeds from the Polish Offering, which
were being held in escrow by the Offering Agent, have been returned to the respective investors.
The Advisor and the Placement Agent have proposed
an alternative strategy for achieving a listing on the NewConnect Market, which would utilize a “reverse merger” structure
involving a to-be-established Polish subsidiary of the Company and an entity already listed on the NewConnect Market. The Company
is currently reviewing this proposal but no determination has been made as to whether such an alternative listing approach would
be feasible.
The Company is currently in discussions with
other parties regarding alternative financing arrangements.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
CARDIOGENICS HOLDINGS INC. |
|
|
|
|
By: |
/s/
Yahia Gawad |
|
Name: |
Yahia Gawad |
|
Title: |
Chief Executive Officer |
Dated: August 11, 2014
CardioGenics (CE) (USOTC:CGNH)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
CardioGenics (CE) (USOTC:CGNH)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025